Table 3.
IC501 towards Thrombin in WRPs (μg/mL) | |||||
---|---|---|---|---|---|
Bioactive Compound |
Median | Min | Max | Geometric Mean | 95% Confidence Interval |
Clarithromycin | 105.6 | 88.3 | 119.5 | 103.7 | 71.0 thru 151.3 |
Azithromycin | 13.6 | 11.9 | 14.5 | 13.3 | 10.3 thru 17.1 |
Linezolid | 98.0 | 93.0 | 110.1 | 100.1 | 80.8 thru 124.1 |
Amikacin | 22.0 | 18.7 | 27.3 | 22.4 | 14.0 thru 36.0 |
Netilmicin | 6.6 | 5.7 | 8.1 | 6.7 | 4.3 thru 10.4 |
Daptomycin | 42.7 | 33.7 | 45.9 | 40.4 | 27.1 thru 60.4 |
Piperacillin/Tazobactam | 142.3/17.8 | 123.6/15.6 | 170.1/20.8 | 144.1/17.9 | 96.8 thru 214.4/12.5 thru 25.7 |
Ceftazidime | 99.2 | 82.8 | 115.3 | 98.2 | 65.0 thru 148.3 |
Tigecycline | 262.0 | 222.7 | 311.6 | 262.9 | 173.2 thru 399.1 |
Vancomycin | 354.0 | 312.7 | 388.5 | 350.3 | 267.3 thru 459.2 |
Meropenem | ND | - | - | - | - |
Experiments were conducted three times using different platelets preparations. 1IC50 values are expressed as μg/mL of bioactive compound in the aggregometer cuvette. Final concentration of thrombin in the aggregometer cuvette was 0.01 mU in WRPs. WRPs: Washed Rabbit Platelets; ND: Not detected inhibition against thrombin-induced platelet aggregation.